Although open-label design could have a greater tendency to bias results in trials that evaluate subjective outcomes such as pain, we found no evidence that this occurred here, as there was no statistical heterogeneity among head-to-head trials. We agree with O'Connor that publication bias is an important issue to consider. We did not include unpublished studies because results often change significantly between early presentation and final publication, and it is often difficult to adequately assess their methods and study quality. 4 The unpublished trial cited by O'Connor found trends towards higher rates of pain relief among patients treated with 1200 or 2400 mg/day of gabapentin versus placebo, though only the 1200 mg arm reached statistical significance. 5 Its inclusion would have attenuated the efficacy estimate from placebocontrolled trials of gabapentin, thus increasing the discrepancy between direct and indirect estimates. Effects of publication bias are difficult to predict, however, as graphical and statistical tests suggest its presence in placebo-controlled trials of tricyclics, but not gabapentin. We thank O'Connor for pointing out an error in data abstraction from a trial by Gorson et al. 6 We based our analysis on the number of patients randomized in the first crossover period rather than on all patients enrolled. Using the correct data (17/40 vs. 9/40), one finds the estimate for pain relief in placebo-controlled gabapentin trials is virtually identical to the estimate presented in our article (pooled relative risk 2.17 [95% CI 1.76 to 2.67]), and there is no effect on the indirect estimate.
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We do not agree that indirect comparisons remain the best source of information on relative efficacy of gabapentin versus tricyclics. Compared to the gabapentin trials, the placebocontrolled tricyclic trials had more methodological shortcomings, more frequently used a crossover design, reported lower placebo response rates, and had findings that suggested publication bias. All of these factors violate the critical assumption underlying indirect comparisons-that treatment effects should be consistent across all studies. 7 The fact that a large discrepancy between direct and indirect comparisons is present after the publication of only a handful of head-to-head trials underscores the need for more evidence, but doesn't make problematic indirect comparisons any more valid. 
